{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:47:29Z","timestamp":1787950049118,"version":"build-2784847793"},"reference-count":42,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We report findings from a post\u2010marketing study conducted from November 2016 to September 2022, which evaluated the safety and effectiveness of ixekizumab in Japanese patients with psoriasis under routine clinical practice for up to 52\u2009weeks, and the incidence of serious infections and malignancies for up to 3\u2009years. Of 804 patients in this analysis (67.9% male; median age, 54\u2009years; mean disease duration, 11.8\u2009years), 72.9%, 37.7%, 7.8%, and 3.7% had psoriasis vulgaris, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis, respectively (subtypes not mutually exclusive). At 52\u2009weeks, adverse events were reported in 203 patients (25.3%). Serious adverse events were reported in 36 patients (4.5%), including serious infections and infestations (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200913, 1.6%). The incidence of serious infections and benign, malignant, and unspecified neoplasms was 0.8% (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20095) and 0.6% (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20094) respectively, at 3\u2009years. Overall, 137 patients (17.0%) received Q2\/Q2 treatment (160\u2009mg starting dose, followed by 80\u2009mg every 2\u2009weeks from week 12); 550 patients (68.4%) received Q2\/Q4 treatment (160\u2009mg starting dose, followed by 80\u2009mg every 2\u2009weeks from weeks 2 to 12 and 80\u2009mg every 4\u2009weeks thereafter); and 117 patients (14.6%) discontinued before week 12 or received only one dose after week 12. A higher proportion of patients in the Q2\/Q2 group had psoriatic arthritis (56.9% [\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200978]) compared with the Q2\/Q4 group (32.9% [\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009181]). Among patients in the Q2\/Q2 versus the Q2\/Q4 dose groups, 21 (15.3%) and 141 (25.6%) respectively had adverse events and 2 (1.5%) and 32 (5.8%) respectively had serious adverse events. The mean Psoriasis Area and Severity Index score and body surface area percentage significantly decreased from baseline to week 52 for all psoriasis subtypes and by Q2\/Q2 and Q2\/Q4 ixekizumab doses (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01 or\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Overall, the safety and effectiveness of ixekizumab in real\u2010world settings in Japan were similar to those reported in clinical trials.\n                  <\/jats:p>","DOI":"10.1111\/1346-8138.17695","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T08:11:05Z","timestamp":1741853465000},"page":"787-801","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and effectiveness of ixekizumab in Japanese patients with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis: Post\u2010marketing surveillance"],"prefix":"10.1111","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2123-3033","authenticated-orcid":false,"given":"Hideshi","family":"Torii","sequence":"first","affiliation":[{"name":"Division of Dermatology Tokyo Yamate Medical Center  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Geriatric and Environmental Dermatology Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K.  Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Dong","sequence":"additional","affiliation":[{"name":"Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K.  Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Tsujimoto","sequence":"additional","affiliation":[{"name":"Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K.  Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7596-2579","authenticated-orcid":false,"given":"Takashi","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K.  Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3200-2882","authenticated-orcid":false,"given":"Hitoe","family":"Torisu\u2010Itakura","sequence":"additional","affiliation":[{"name":"Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K.  Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7845-6698","authenticated-orcid":false,"given":"Mamitaro","family":"Ohtsuki","sequence":"additional","affiliation":[{"name":"Department of Dermatology Jichi Medical University  Shimotsuke Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1095-0355","authenticated-orcid":false,"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[{"name":"Department of Dermatology Nippon Medical School  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006450"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16423"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141598"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14523"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S288345"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00881-0"},{"key":"e_1_2_9_9_1","first-page":"93","article-title":"Erythrodermic psoriasis: pathophysiology and current treatment perspectives","volume":"6","author":"Singh RK","year":"2016","journal-title":"Psoriasis"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.880201"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743180"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01655-6"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60125-8"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.11.022"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez684"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06218-8"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-023-00605-6"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12773"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13622"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15287"},{"key":"e_1_2_9_24_1","unstructured":"Pharmaceuticals and Medical Devices Agency.Approval of ixekizumab.2016[cited 2024 Apr 09]. Available from:www.pmda.go.jp\/files\/000224346.pdf"},{"key":"e_1_2_9_25_1","unstructured":"Pharmaceuticals and Medical Devices Agency.Approval of ixekizumab.2018[cited 2024 Apr 09]. Available from:www.pmda.go.jp\/files\/000235288.pdf"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00666-x"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"e_1_2_9_28_1","unstructured":"Van VoorheesAS FeldmanSR LebwohlMG OrbaiAM RitchlinC National Psoriasis Foundation.The psoriasis and psoriatic arthritis pocket guide: treatment algorithms and management options. 2023. [cited 2024 Jul 16]. Available from:https:\/\/npf\u2010website.cdn.prismic.io\/npf\u2010website\/d4fbd2f3\u2010cc81\u20104a0b\u2010a503\u2010ad510bd2bfd2_NPF_EO_PocketGuide_2023.pdf"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380106"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08832.x"},{"key":"e_1_2_9_32_1","unstructured":"Food and Drug Administration.Real\u2010world evidence.2022[cited 2024 Apr 11]. Available from:https:\/\/www.fda.gov\/science\u2010research\/science\u2010and\u2010research\u2010special\u2010topics\/real\u2010world\u2010evidence"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16426"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0024"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.3056"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00743-9"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16644"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18376"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01086-9"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2160196"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911128"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2059051"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19147"}],"updated-by":[{"DOI":"10.1111\/1346-8138.17976","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000}}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.17695","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.17695","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.17695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T17:39:05Z","timestamp":1772991545000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.17695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1111\/1346-8138.17695"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.17695","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"2024-09-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}